NEW BRUNSWICK, N.J.,
Jan. 17, 2019 /PRNewswire/ -- Johnson
& Johnson (NYSE:JNJ) today announced the completion of the
acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company")
for a total purchase price of approximately ¥230 billion. The
acquisition was completed through a series of transactions that
included an all-cash tender offer to acquire publicly held shares
of the Company for ¥5,900 per share. Johnson & Johnson
plans to acquire the remaining shares of the Company that were not
tendered in the tender offer through a share consolidation under
Japanese law during the first half of 2019 and take appropriate
actions to delist the Company from the Tokyo Stock Exchange.
The Company, which markets the DR. CI:LABO, LABO LABO and GENOMER line of skincare products,
will now become part of the Johnson & Johnson Family of
Consumer Companies.
"The addition of DR. CI:LABO, LABO
LABO and GENOMER to our franchise strengthens our growing
beauty portfolio with unique dermocosmetic innovation," said
Jorge Mesquita, Worldwide Chairman,
Johnson & Johnson Consumer. "We are very pleased to complete
this important transaction and look forward to bringing
efficacious, science-backed skincare products to our health and
beauty consumers around the world."
Any EPS impact of the transaction will be included in the 2019
guidance provided on Johnson & Johnson's Q4 2018 earnings
call.
About Johnson & Johnson
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NOTE CONCERNING FORWARD-LOOKING STATEMENTS
This press
release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding the
potential transaction between Johnson &
Johnson and the Company. The reader is cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections of Johnson &
Johnson and the Company. Risks and uncertainties include,
but are not limited to: the satisfaction of closing conditions for
the transaction, including the receipt of regulatory approvals for
the transaction; the tender of the requisite amount of the
outstanding shares of the Company; the possibility that the
transaction will not be completed in the expected timeframe or at
all; the potential that the expected benefits and opportunities of
the transaction, if completed, may not be realized or may take
longer to realize than expected; uncertainty of commercial success
for new and existing products; manufacturing difficulties and
delays; economic conditions, including currency exchange and
interest rate fluctuations; competition, including technological
advances, new products and patents attained by competitors; changes
to applicable laws and regulations, including tax laws and domestic
and foreign health care reforms; adverse litigation or government
action; changes in behavior and spending patterns or financial
distress of purchasers of health care products and services; and
trends toward health care cost containment. In addition, if and
when the transaction is consummated, there will be risks and
uncertainties related to the ability of the Johnson &
Johnson Family of Companies to successfully integrate the
products, employees and operations of the Company, as well as
the ability to ensure continued performance or market growth
of the Company's products. A further list and description
of these risks, uncertainties and other factors can be found
in Johnson & Johnson's publicly available filings
with the U.S. Securities and Exchange Commission. Copies of
these filings, as well as subsequent filings, are available online
at www.sec.gov, www.jnj.com or on request
from Johnson & Johnson. Johnson & Johnson does
not undertake to update any forward-looking statement as a result
of new information or future events or developments.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-completes-acquisition-of-ciz-holdings-co-ltd-300779668.html
SOURCE Johnson & Johnson